Optimization of expression conditions for production of anti-colorectal cancer monoclonal antibody CO17-1A in baculovirus-insect cell system. 2011

Da-Young Park, and Jung-Hwan Lee, and Yang-Kang So, and Young-Kwan Kim, and Kinarm Ko, and Sang-Won Park, and Yong Seok Lee, and Yeon Soo Han, and Kisung Ko
Department of Biological Science, Biotechnology Institute, College of Natural Sciences, Wonkwang University, Iksan, Korea.

The baculovirus-insect cell system is considered a feasible expression system for recombinant glycoprotein production due to its several advantages, including high capacity, flexibility, and glycosylation capability. However, accurate titering of the recombinant baculovirus is required to ensure high expression in insect cells using a commercial and expensive immunoassay titer kit in which the envelope glycoprotein of the Autographa californica multiple nucleopolyhedrovirus (AcMNPV)-type baculovirus is detected by anti-envelope glycoprotein antibody and a secondary antibody conjugated to horseradish peroxidase (HRP). In this study, conditions for the expression of the CO17-1A immunotherapeutic monoclonal antibody (MAb) against colorectal cancer cells in a baculovirus system were optimized without using a commercial titering kit. Several variables were investigated to optimize antibody expression in a baculovirus-insect cell system, including baculovirus passage, volume of the infecting baculovirus inoculum (100, 200, 400, and 800 μL), and the harvest time of insect cells or cell supernatants after virus infection (24, 48, and 72 h). Two different pFastBac vectors carrying the CO17-1A MAb genes with or without the KDEL endoplasmic reticulum (ER) retention motif (Lys-Asp-Glu-Leu) fused to the HC (MAb CO17-1A K and MAb CO17-1A, respectively) were constructed and used to generate baculoviruses. Immunoblot analysis was conducted to confirm expression of MAb CO17-1A K and MAb CO17-1A in baculovirus-infected insect cells. Densitometry analysis of the protein bands was used to quantify the relative expression under different conditions. The highest expression was observed in lysed cells infected with 400 μL of passage 3 baculovirus (P(3) BV) carrying the gene encoding the CO17-1A MAb without KDEL at 72 h after virus infection. These results suggest that the infection conditions, the number of virus passages, baculovirus inoculum volume, and the harvest time can be modified to optimize MAb expression without using a BaculoELISA titer kit in a baculovirus-insect cell system.

UI MeSH Term Description Entries
D011993 Recombinant Fusion Proteins Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes. Fusion Proteins, Recombinant,Recombinant Chimeric Protein,Recombinant Fusion Protein,Recombinant Hybrid Protein,Chimeric Proteins, Recombinant,Hybrid Proteins, Recombinant,Recombinant Chimeric Proteins,Recombinant Hybrid Proteins,Chimeric Protein, Recombinant,Fusion Protein, Recombinant,Hybrid Protein, Recombinant,Protein, Recombinant Chimeric,Protein, Recombinant Fusion,Protein, Recombinant Hybrid,Proteins, Recombinant Chimeric,Proteins, Recombinant Fusion,Proteins, Recombinant Hybrid
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003001 Cloning, Molecular The insertion of recombinant DNA molecules from prokaryotic and/or eukaryotic sources into a replicating vehicle, such as a plasmid or virus vector, and the introduction of the resultant hybrid molecules into recipient cells without altering the viability of those cells. Molecular Cloning
D004721 Endoplasmic Reticulum A system of cisternae in the CYTOPLASM of many cells. In places the endoplasmic reticulum is continuous with the plasma membrane (CELL MEMBRANE) or outer membrane of the nuclear envelope. If the outer surfaces of the endoplasmic reticulum membranes are coated with ribosomes, the endoplasmic reticulum is said to be rough-surfaced (ENDOPLASMIC RETICULUM, ROUGH); otherwise it is said to be smooth-surfaced (ENDOPLASMIC RETICULUM, SMOOTH). (King & Stansfield, A Dictionary of Genetics, 4th ed) Ergastoplasm,Reticulum, Endoplasmic
D005822 Genetic Vectors DNA molecules capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. Many are derived from PLASMIDS; BACTERIOPHAGES; or VIRUSES. They are used for transporting foreign genes into recipient cells. Genetic vectors possess a functional replicator site and contain GENETIC MARKERS to facilitate their selective recognition. Cloning Vectors,Shuttle Vectors,Vectors, Genetic,Cloning Vector,Genetic Vector,Shuttle Vector,Vector, Cloning,Vector, Genetic,Vector, Shuttle,Vectors, Cloning,Vectors, Shuttle
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000951 Antigens, Neoplasm Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. Neoplasm Antigens,Tumor Antigen,Tumor Antigens,Antigen, Tumor,Antigens, Tumor
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D014162 Transfection The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES. Transfections

Related Publications

Da-Young Park, and Jung-Hwan Lee, and Yang-Kang So, and Young-Kwan Kim, and Kinarm Ko, and Sang-Won Park, and Yong Seok Lee, and Yeon Soo Han, and Kisung Ko
February 2009, Hybridoma (2005),
Da-Young Park, and Jung-Hwan Lee, and Yang-Kang So, and Young-Kwan Kim, and Kinarm Ko, and Sang-Won Park, and Yong Seok Lee, and Yeon Soo Han, and Kisung Ko
July 1986, Hybridoma,
Da-Young Park, and Jung-Hwan Lee, and Yang-Kang So, and Young-Kwan Kim, and Kinarm Ko, and Sang-Won Park, and Yong Seok Lee, and Yeon Soo Han, and Kisung Ko
May 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy,
Da-Young Park, and Jung-Hwan Lee, and Yang-Kang So, and Young-Kwan Kim, and Kinarm Ko, and Sang-Won Park, and Yong Seok Lee, and Yeon Soo Han, and Kisung Ko
July 1986, Hybridoma,
Da-Young Park, and Jung-Hwan Lee, and Yang-Kang So, and Young-Kwan Kim, and Kinarm Ko, and Sang-Won Park, and Yong Seok Lee, and Yeon Soo Han, and Kisung Ko
December 2020, Scientific reports,
Da-Young Park, and Jung-Hwan Lee, and Yang-Kang So, and Young-Kwan Kim, and Kinarm Ko, and Sang-Won Park, and Yong Seok Lee, and Yeon Soo Han, and Kisung Ko
May 1989, Proceedings of the National Academy of Sciences of the United States of America,
Da-Young Park, and Jung-Hwan Lee, and Yang-Kang So, and Young-Kwan Kim, and Kinarm Ko, and Sang-Won Park, and Yong Seok Lee, and Yeon Soo Han, and Kisung Ko
January 2016, BMC research notes,
Da-Young Park, and Jung-Hwan Lee, and Yang-Kang So, and Young-Kwan Kim, and Kinarm Ko, and Sang-Won Park, and Yong Seok Lee, and Yeon Soo Han, and Kisung Ko
July 1986, Hybridoma,
Da-Young Park, and Jung-Hwan Lee, and Yang-Kang So, and Young-Kwan Kim, and Kinarm Ko, and Sang-Won Park, and Yong Seok Lee, and Yeon Soo Han, and Kisung Ko
January 2012, Methods in molecular biology (Clifton, N.J.),
Da-Young Park, and Jung-Hwan Lee, and Yang-Kang So, and Young-Kwan Kim, and Kinarm Ko, and Sang-Won Park, and Yong Seok Lee, and Yeon Soo Han, and Kisung Ko
January 2014, Biotechnology progress,
Copied contents to your clipboard!